Neurology Minute

In part one of this two-part series, Dr. Gregg Day and Dr. Sebastian Palmqvist discuss the top-line findings from the study exploring the diagnostic performance of blood biomarkers for Alzheimer disease in clinical cohorts. Show reference: https://jamanetwork.com/journals/jama/fullarticle/2821669   

In part one of this two-part series, Dr. Jeff Ratliff and Dr. Calium discuss the risk of developing dementia among patients with MCI at three or five-year time points. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209499   

Dr. Jeff Ratliff talks about the FDA approval of Crexont for the treatment of Parkinson disease.  Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2808496

Dr. Jeff Ratliff discusses an exciting study in the world of deep brain stimulation for Parkinson disease.  Show reference: https://www.nature.com/articles/s41591-024-03196-z

Dr. Tesha Monteith talks about the efficacy of atogepant for the preventive treatment of chronic migraine in participants with and without acute medication overuse. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209584   

Dr. Stacey Clardy and Dr. Nicola de Souza discuss how to improve care in the clinic for these veterans and military service members. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209417

In the first installment of this two-part series, Dr. Jeff Ratliff and Dr. Daniel Weintraub discuss the risks associated with the development of dementia in patients diagnosed with Parkinson disease. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209699 

In part two of this two-part series, Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss why clinicians should be cautious when relying too much on dopaminergic imaging. Show reference: https://doi.org/10.1212/WNL.0000000000209453 

In part two of this two-part series, Dr. Tesha Monteith discusses the key features of long COVID.   Show reference: https://doi.org/10.17226/27768

In part one of this two-part series, Dr. Tesha Monteith discusses the 2024 National Academies of Sciences, Engineering, and Medicine formal definition of long COVID.  Show reference: https://doi.org/10.17226/27768

Dr. Jeff Ratliff and Dr. Eduardo De Pablo-Fernández discuss the strengths of dopamine transporter imaging or DAT imaging in diagnosing patients with Parkinsonian disorders. Show references: https://doi.org/10.1212/WNL.0000000000209453 

Dr. Dan Ackerman and Dr. Luciano A. Sposato discuss the topic of embolic stroke of undetermined sources and the controversies surrounding cardiac monitoring and anticoagulation. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209535 

Dr. Tesha Monteith provides an overview of the updated position statement on migraine prevention by the American Headache Society.  

In part two of this two-part series, Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the differences in treatment between American Stroke Centers and those in France. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398  

Dr. Meagan Seay discusses a relatively recently described but very interesting phenomenon called transient smartphone blindness. This is a phenomenon causing acute, painless, transient, monocular vision loss associated with smartphone use while lying down in the dark. Show reference: Transient Smartphone Blindness - EyeWiki 

Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the efficacy and safety of both thrombolytics in patients with large ischemic core.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398  

Dr. Jason Crowell and Dr. Colin Hoy discuss the concept of prodromal Parkinson disease and the ethical considerations surrounding its diagnosis.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209522 

In the last episode of this three-part series, Dr. Jeff Ratliff discusses how to approach patients presenting with emergent rigidity and difficulty moving.

In the second episode of this three-part series, Dr. Jeff Ratliff provides a rapid overview of hyperkinetic disorders that require urgent attention.

In the first episode of this three-part series, Dr. Jeff Ratliff discusses a few key points to help recognize and initiate treatment for patients with movement disorder emergencies, focusing on the initial approach to these disorders. It is important to consider medications, labs, and imaging as part of the evaluation process.